USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Glaxo Group Limited

USPTO PatentsView assignee record - 130 granted patents across 25 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Glaxo ranks #2,929 of 49,997 tracked US assignees by granted-patent volume, with 130 patents across 25 technology areas.

#2,929
of 49,997 US assignees by volume
Top 28%
by Innovation Score (43.6/100)
13.8
avg claims per patent
-89%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2929 · Foreign Corporation #2,929 · 130 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MID 130 grants
  • TOP-DECILE #2,929/49,997
  • PHOTO-FINISH Alcon Research
  • CPC-FOCUS A61P · 25 areas
  • INNOV-PAR 43.6/100
  • CLAIMS-RICH 13.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -89% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Alcon Research, Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Glaxo

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Glaxo's Innovation Score is 43.6/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Glaxo's grants concentrate

Glaxo Group Limited is a focused PatentsView assignee: 25 CPC subclasses with 69.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (44 grants) versus a trough of 1 in 2022. By volume, Glaxo sits between Alcon Research, Ltd. and MTU Friedrichshafen GMBH.

Glaxo's three-year grant acceleration

Glaxo Group Limited shows 2 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Glaxo's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Glaxo holds 130 patents at rank #2,929, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Glaxo

By rank, the assignees closest to #2,929 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Glaxo's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Glaxo, neither rank-band nor same-CPC leaders (those blocks stay above).

Glaxo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

01020304050 2015201620172018201920202021202220232025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Glaxo Group Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 44 33.8%
2016 40 30.8%
2017 20 15.4%
2018 5 3.8%
2019 7 5.4%
2020 7 5.4%
2021 4 3.1%
2022 1 0.8%
2023 1 0.8%
2025partial year 1 0.8%

Which technologies does Glaxo Group Limited patent most?

Top 15 of 25 technology areas

Where it ranks

Overall rank by patents

#2,929

of 49,997 tracked assignees

Innovation Score

43.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Glaxo Group Limited's patent record in context - here's where to go next.

  • Glaxo Group Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 69.2% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #2,929 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Glaxo Group Limited against Alcon Research, Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 43.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.